These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 37094524)

  • 21. Bortezomib enhances cytotoxicity of ex vivo-expanded gamma delta T cells against acute myeloid leukemia and T-cell acute lymphoblastic leukemia.
    Story JY; Zoine JT; Burnham RE; Hamilton JAG; Spencer HT; Doering CB; Raikar SS
    Cytotherapy; 2021 Jan; 23(1):12-24. PubMed ID: 33168453
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia.
    Romee R; Rosario M; Berrien-Elliott MM; Wagner JA; Jewell BA; Schappe T; Leong JW; Abdel-Latif S; Schneider SE; Willey S; Neal CC; Yu L; Oh ST; Lee YS; Mulder A; Claas F; Cooper MA; Fehniger TA
    Sci Transl Med; 2016 Sep; 8(357):357ra123. PubMed ID: 27655849
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-affinity CD16 integration into a CRISPR/Cas9-edited CD38 locus augments CD38-directed antitumor activity of primary human natural killer cells.
    Clara JA; Levy ER; Reger R; Barisic S; Chen L; Cherkasova E; Chakraborty M; Allan DSJ; Childs R
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35135865
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting CD157 in AML using a novel, Fc-engineered antibody construct.
    Krupka C; Lichtenegger FS; Köhnke T; Bögeholz J; Bücklein V; Roiss M; Altmann T; Do TU; Dusek R; Wilson K; Bisht A; Terrett J; Aud D; Pombo-Villar E; Rohlff C; Hiddemann W; Subklewe M
    Oncotarget; 2017 May; 8(22):35707-35717. PubMed ID: 28415689
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia.
    Märklin M; Hagelstein I; Koerner SP; Rothfelder K; Pfluegler MS; Schumacher A; Grosse-Hovest L; Jung G; Salih HR
    J Immunother Cancer; 2019 May; 7(1):143. PubMed ID: 31142382
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells.
    Igarashi T; Wynberg J; Srinivasan R; Becknell B; McCoy JP; Takahashi Y; Suffredini DA; Linehan WM; Caligiuri MA; Childs RW
    Blood; 2004 Jul; 104(1):170-7. PubMed ID: 15016654
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities.
    Christodoulou I; Ho WJ; Marple A; Ravich JW; Tam A; Rahnama R; Fearnow A; Rietberg C; Yanik S; Solomou EE; Varadhan R; Koldobskiy MA; Bonifant CL
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34896980
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Natural killer cells differentiated in vitro from cord blood CD34
    Domogala A; Blundell M; Thrasher A; Lowdell MW; Madrigal JA; Saudemont A
    Cytotherapy; 2017 Jun; 19(6):710-720. PubMed ID: 28428057
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Significance of Frequencies, Compositions, and/or Antileukemic Activity of (DC-stimulated) Invariant NKT, NK and CIK Cells on the Outcome of Patients With AML, ALL and CLL.
    Boeck CL; Amberger DC; Doraneh-Gard F; Sutanto W; Guenther T; Schmohl J; Schuster F; Salih H; Babor F; Borkhardt A; Schmetzer H
    J Immunother; 2017; 40(6):224-248. PubMed ID: 28557814
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined Blockade of TIGIT and CD39 or A2AR Enhances NK-92 Cell-Mediated Cytotoxicity in AML.
    Brauneck F; Seubert E; Wellbrock J; Schulze Zur Wiesch J; Duan Y; Magnus T; Bokemeyer C; Koch-Nolte F; Menzel S; Fiedler W
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884723
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Constitutive expression and role of the TNF family ligands in apoptotic killing of tumor cells by human NK cells.
    Kashii Y; Giorda R; Herberman RB; Whiteside TL; Vujanovic NL
    J Immunol; 1999 Nov; 163(10):5358-66. PubMed ID: 10553060
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ligands for natural killer cell-activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias.
    Nowbakht P; Ionescu MC; Rohner A; Kalberer CP; Rossy E; Mori L; Cosman D; De Libero G; Wodnar-Filipowicz A
    Blood; 2005 May; 105(9):3615-22. PubMed ID: 15657183
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HLA-DR-, CD33+, CD56+, CD16- myeloid/natural killer cell acute leukemia: a previously unrecognized form of acute leukemia potentially misdiagnosed as French-American-British acute myeloid leukemia-M3.
    Scott AA; Head DR; Kopecky KJ; Appelbaum FR; Theil KS; Grever MR; Chen IM; Whittaker MH; Griffith BB; Licht JD
    Blood; 1994 Jul; 84(1):244-55. PubMed ID: 7517211
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Engineering CAR-NK cells targeting CD33 with concomitant extracellular secretion of anti-CD16 antibody revealed superior antitumor effects toward myeloid leukemia.
    Zhang R; Liu Q; Zhou S; He H; Zhao M; Ma W
    Cancer Lett; 2023 Apr; 558():216103. PubMed ID: 36805460
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis.
    Smyth MJ; Cretney E; Takeda K; Wiltrout RH; Sedger LM; Kayagaki N; Yagita H; Okumura K
    J Exp Med; 2001 Mar; 193(6):661-70. PubMed ID: 11257133
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Membrane-bound TRAIL supplements natural killer cell cytotoxicity against neuroblastoma cells.
    Sheard MA; Asgharzadeh S; Liu Y; Lin TY; Wu HW; Ji L; Groshen S; Lee DA; Seeger RC
    J Immunother; 2013 Jun; 36(5):319-29. PubMed ID: 23719242
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells.
    Zhu C; Song Z; Wang A; Srinivasan S; Yang G; Greco R; Theilhaber J; Shehu E; Wu L; Yang ZY; Passe-Coutrin W; Fournier A; Tai YT; Anderson KC; Wiederschain D; Bahjat K; Adrián FJ; Chiron M
    Front Immunol; 2020; 11():1771. PubMed ID: 32922390
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activated human NK and CD8+ T cells express both TNF-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors but are resistant to TRAIL-mediated cytotoxicity.
    Mirandola P; Ponti C; Gobbi G; Sponzilli I; Vaccarezza M; Cocco L; Zauli G; Secchiero P; Manzoli FA; Vitale M
    Blood; 2004 Oct; 104(8):2418-24. PubMed ID: 15205263
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relation of natural killer cell line NK-92-mediated cytolysis (NK-92-lysis) with the surface markers of major histocompatibility complex class I antigens, adhesion molecules, and Fas of target cells.
    Komatsu F; Kajiwara M
    Oncol Res; 1998; 10(10):483-9. PubMed ID: 10338151
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients.
    Siegler U; Meyer-Monard S; Jörger S; Stern M; Tichelli A; Gratwohl A; Wodnar-Filipowicz A; Kalberer CP
    Cytotherapy; 2010 Oct; 12(6):750-63. PubMed ID: 20491532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.